Antibiotic Selection in Patients at Risk for Clostridioides difficile Infection
Augmentin (amoxicillin-clavulanate) is an antibiotic associated with increased risk of Clostridioides difficile infection (CDI), so it is generally not the preferred choice when safer alternatives with equivalent clinical efficacy are available. [1, 2] CDI risk mitigation focuses on minimizing exposure to higher-risk antibiotics, using the shortest effective duration, and avoiding unnecessary antibiotics. [1]
Core Recommendation and Strength of Recommendation
Antibiotic stewardship should prioritize minimizing use of antibiotics that pose higher CDI risk. [1] CDC guidance specifically emphasizes assessing appropriateness of antibiotic prescribing that poses the highest risk for CDI and ensuring the shortest effective duration of antibiotic therapy. [1]
Medication Selection Algorithm
Antibiotics for an infection should be selected to minimize CDI risk while maintaining appropriate antimicrobial coverage. [1]
Medication class considerations supported by CDI prevention guidance and observational evidence include:
- “Highest-risk” broad-spectrum antibiotics should be minimized (examples cited by CDC include fluoroquinolones, carbapenems, and 3rd or 4th generation cephalosporins). [1]
- Amoxicillin-clavulanate is associated with increased CDI risk compared with no exposure in population data. [2]
Key Evidence Supporting CDI Risk With Amoxicillin-Clavulanate
A pharmacopoeia-wide case-cohort study found amoxicillin-clavulanate was among the largest contributors to CDI risk, with an adjusted odds ratio (OR) of 6.05 (95% CI 5.69 to 6.43). [2] A retrospective multicenter cohort study in hospitalized patients with aspiration pneumonia found that extended anaerobic coverage regimens that included amoxicillin-clavulanate were associated with higher CDI colitis rates after admission (0.8% to 1.1% vs ≤0.2% with limited anaerobic coverage). [3]
Monotherapy Versus Combination Therapy
Avoidance of CDI-promoting antibiotic exposure is a prevention principle across both monotherapy and combination regimens. [1] In practice, adding coverage that increases spectrum without clinical indication increases CDI risk exposure and should be avoided. [3]
Initiation Thresholds and Indications
No guideline provides a specific blood-draw threshold or formal CDI-risk score cutoff that dictates when amoxicillin-clavulanate becomes contraindicated. CDI risk reduction is instead based on antibiotic stewardship principles: selection of appropriate agents, avoidance of unnecessary antibiotics, and shortest effective duration. [1]
Common Pitfalls to Avoid
Pitfall: Prolonged or unnecessary broad-spectrum antibiotic exposure increases CDI risk. [1] Pitfall: Escalation to broader anaerobic coverage without clear indication increases CDI risk in clinical cohorts. [3]
Targets or Goals of Therapy
The CDI prevention goal is minimization of high-risk antibiotic exposure. [1] The treatment-duration goal is use of the shortest effective duration of antibiotic therapy, including alignment of inpatient and post-discharge duration. [1]
Clinical Determination of “Appropriate” for Augmentin
Augmentin is appropriate only when it provides necessary coverage for the diagnosed infection and no lower-CDI-risk alternative with equivalent efficacy is available. [1, 2] When antibiotic therapy is required, risk should be reduced by choosing the narrowest effective agent and ensuring a shortest effective duration. [1]